Alternative Agents to Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections

Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing the cfr Methyltransferase Gene or Ribosomal Mutations

(2010) J. B. Locke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges

(2010) S. D. Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing

(2010) A. Belley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection

(2010) G. Ralph Corey et al.   CLINICAL INFECTIOUS DISEASES

In vitro activity of oritavancin against community-associated meticillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)

(2010) Louis D. Saravolatz et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical Outbreak of Linezolid-Resistant Staphylococcus aureus in an Intensive Care Unit

(2010) Miguel Sánchez García   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Health Care–Associated Invasive MRSA Infections, 2005-2008

(2010) Alexander J. Kallen   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

(2010) H. Moisan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates

(2009) F. F. Arhin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of Dalbavancin against a Worldwide Collection of 81,673 Gram-Positive Bacterial Isolates

(2009) D. J. Biedenbach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Linezolid surveillance program results for 2008 (LEADER Program for 2008)

(2009) David J. Farrell et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)

(2009) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections

(2009) Elizabeth D Hermsen et al.   Expert Opinion On Drug Safety

A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin

(2009) Michael T Guskey et al.   PHARMACOTHERAPY

Clinical and Financial Outcomes Due to Methicillin Resistant Staphylococcus aureus Surgical Site Infection: A Multi-Center Matched Outcomes Study

(2009) Deverick J. Anderson et al.   PLoS One

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria

(2008) K. M. Krause et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

(2008) Y. Ge et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections

(2008) G. J. Noel et al.   CLINICAL INFECTIOUS DISEASES

Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms

(2008) Martin E. Stryjewski et al.   CLINICAL INFECTIOUS DISEASES

Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007

(2008) Michael J. Dowzicky et al.   CLINICAL THERAPEUTICS

Antimicrobial activity of ceftobiprole, a novel anti–methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006)

(2008) Thomas R. Fritsche et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus

(2008) Ian M. Gould   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

(2008) D. C. Draghi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

(2008) I. Florescu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers

(2007) Rodrigo E. Mendes et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE